California’s Kite strikes deals with Fosun and Daiichi Sankyo.
But analysts excited by promise of next generation of medicines.
Shares rise following announcement.
Soliris fails when used to treat post-transplant complications.
US biotech seeks conditional approval for eteplirsen in EU.
Funding could be unsustainable, says review.
Reports suggest Sanofi could pay $30 billion for Swiss biotech.
New facility in Cambridge, Massachusetts.
mHealth tech can provide longer-term monitoring for clinical trials.